Arcadia Biosciences' Q4 revenue falls 26%, net loss narrows

Arcadia Biosciences

26/03/2026 20:22

Overview

U.S. wellness products maker's Q4 revenue fell 26% yr/yr due partly to lower Zola and absence GLA oil sales

Net loss attributable to common stockholders narrowed, helped by lower SG&A expenses

Roosevelt Resources ended proposed merger with Arcadia; co raised $2.1 mln via preferred options

Outlook

Company intends to use recent proceeds to grow Zola coconut water brand and evaluate strategic alternatives

Arcadia says it will require additional funding in the near future to continue operations

Result Drivers

LOWER ZOLA AND GLA OIL SALES - Q4 revenue decline was in part due to lower Zola sales and absence of GLA oil sales compared to prior year

SG&A EXPENSE REDUCTION - Lower selling, general, and administrative expenses contributed to improved net loss

ZOLA SALES GROWTH (FULL YEAR) - Zola revenues rose 17% yr/yr for 2025, driven by increased distribution and higher sales volume

Company press release: ID:nGNX3sSrfp

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$901,000
Q4 Net Income
-$1.34 mln
Q4 Operating Expenses
$2.28 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)